Fig. 3

Clinical outcomes associated with aEGFR and TP53 mutation clearance. A Kaplan-Meier curves for PFS in patients with and without detectable aEGFR mutations at baseline. Patients without detectable aEGFR mutations had comparable PFS to those with detectable mutations (P = 0.6). B OS comparison in patients with and without detectable aEGFR mutations at baseline, showing no significant difference (P = 0.8). C PFS for patients with detectable aEGFR mutations who achieved clearance of mutations in ctDNA after two treatment cycles compared to those without clearance, demonstrating significantly longer PFS (P < 0.001). D OS comparison between patients with and without aEGFR mutation clearance, showing significantly improved OS in those with mutation clearance (P = 0.005). E PFS in patients with and without baseline TP53 mutations, showing no significant difference (P = 0.7). F OS in patients with and without TP53 mutations at baseline, also demonstrating no significant difference (P = 0.2). G PFS in patients who achieved TP53 mutation clearance after two treatment cycles, showing significantly longer PFS compared to those without clearance (P = 0.005). H OS in patients with TP53 mutation clearance, showing significantly improved OS compared to those without clearance (P = 0.02). PFS, progression-free survival; OS, overall survival; ctDNA, circulating tumor DNA; aEGFR mutations, activating EGFR mutations